Company: SINT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010496
Chunk: 27

Company: Sintx Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 27
---
For the three months ended March 31, 2025, other income
decreased $2.2 million, or -96%, as compared to the same period in 2024. This decrease was primarily due to a $2.7 million decrease in
the change in value of derivative liabilities offset by $0.5 million in offering costs associated with derivative liabilities in the prior
year.

Liquidity and Capital Resources 

The condensed consolidated financial statements have
been prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and settlement
of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability
to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.

For the three months ended March 31, 2025, and 2024,
we incurred net loss of $2.3 million and $0.9 million, respectively, and used cash in operating activities of $1.3 million and
$2.7 million, respectively. We had an accumulated deficit of $284 million and $282 million as of March 31, 2025, and December
31, 2024, respectively. We will require substantial future capital in order to continue operating our business, conduct research and development
and regulatory clearance and approval activities necessary to bring our products to market, and to establish effective marketing and sales
capabilities. Our existing capital resources are not sufficient to enable us to fund the completion of the development and commercialization
of all our product candidates.

To date, our operations have been
principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from
product sales. It is anticipated that we will continue to generate operating losses and use cash in operations. Our continuation as
a going concern is dependent upon our ability to increase sales, decrease expenses and raise additional funding. Whether and when we
can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.

We are actively generating
additional scientific and clinical data to have it published in leading industry publications. We believe the publication of such
data would help sales efforts as we approach new prospects. We are also making additional changes to our sales
strategy, including a focus on revenue growth by expanding the use of silicon nitride in other